Select therapeutic use:
Indications for CYTOVENE IV:
Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients including patients with AIDS. Prevention of CMV disease in high-risk transplant recipients.
Give by IV infusion over 1 hour. Induction for CMV retinitis: 5mg/kg every 12 hours for 14–21 days. Maintenance: 5mg/kg once daily for 7 days per week or 6mg/kg once daily for 5 days per week; if disease progression repeat induction therapy. Prevention of CMV: 5mg/kg every 12 hours for 7–14 days, then 5mg/kg once daily for 7 days per week or 6mg/kg once daily for 5 days per week. Renal impairment, hemodialysis: adjust or reduce dose; see literature.
Monitor CBCs, platelets, ophthalmic, and renal function. Withhold dose if absolute neutrophil count <500cells/microliter or platelet count <25,000cells/microliter. Reduce dose or discontinue if blood dyscrasias occur. Pre-existing cytopenias or history of cytopenic reactions to other drugs, chemicals, or irradiation. Renal impairment. Maintain adequate hydration. Use effective contraception during (men and women) and for at least 90 days after treatment (men). Pregnancy (Cat.C: teratogenic, embryotoxic, carcinogenic, hypospermatogenesis in animals), nursing mothers: not recommended.
Zidovudine increases anemia/neutropenia risk. Caution with nephrotoxic drugs (eg, cyclosporine, amphotericin B). Monitor for toxicity with didanosine. May be potentiated by probenecid. Caution with drugs that inhibit replication of rapidly-dividing cells (eg, dapsone, pentamidine, antineoplastics). Avoid imipenem-cilastatin (seizures).
Neutropenia, anemia, thrombocytopenia, elevated serum creatinine, retinal detachment, fever, GI upset, infections, elevated serum transaminases, inj site reactions, CNS effects, hypertension.